Press Release

The Envisia Genomic Classifier test for idiopathic pulmonary fibrosis (IPF) diagnosis received a draft Medicare local coverage determination (LCD) through the MolDx (Molecular Diagnostics) service program...

A Roswell Park-led research team has linked the development of castration-resistant prostate cancer and resistance to treatment to a lack of androgen...

Horizon Discovery Group, a global leader in gene editing and gene modulation technologies, today announces that is has entered into a collaboration with a global pharma partner to co-develop and apply a novel cutting-edge research tool for target...

10x Genomics, Inc., a company focused on accelerating genomic discovery, today announced that BioLegend and Immudex will be the first 10x Compatible Partners providing products for its new...

Becton Dickinson today announced the commercial release of the BD® AbSeq assay to analyze protein expression at the single-cell level using high-throughput sequencing. The assay brings together high-quality antibodies from the BD Pharmingen™ portfolio with oligonucleotides, allowing researchers to perform ...

Takara Bio USA, Inc has announce that patent JP6336080B—covering the Smart-seq2 method, developed by Rickard Sandberg and exclusively licensed to TBUSA by the Ludwig Institute—has...

Researchers from VIB, Leuven University and University Hospital Leuven studied thousands of healthy and cancerous lung cells to create the first comprehensive atlas of lung tumor cells. Their...

MNG Laboratories, an Atlanta-based neurogenetic testing company, is pleased to announce that it has signed a Distribution Agreement with Pronto Diagnostics, a leading Israeli genomics company, to...

RNA-Seq is a new next-generation assay that can detect gene fusions in solid tumor cells with high accuracy and excellent reproducibility. According to a new report in The Journal of Molecular Diagnostics...

Study flow for the identification of a nasal brush-based classifier of asthma by machine learning analysis of RNAseq data. One hundred and ninety subjects with mild/moderate asthma and controls...